Trade Daiichi Sankyo Company, Limited - 4568 CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 6.04
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment¥1,000Overnight funding adjustmentCharges from full value of position-0.014441 %(-¥3)Trade size with leverage ~ ¥20,000Money from leverage ~ $¥19,000Go to platform: -0.01444%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment¥1,000Overnight funding adjustmentCharges from full value of position-0.007781 %(-¥2)Trade size with leverage ~ ¥20,000Money from leverage ~ $¥19,000Go to platform: -0.00778%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: JPY
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: Japan
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: ¥1,000
• Overnight funding adjustmentCharges from full value of position: -0.014441 %
  (-¥3)

• Margin. Your investment: ¥1,000
• Overnight funding adjustmentCharges from full value of position: -0.007781 %
  (-¥2)

Key Stats

• Prev. Close: 2660.03
• Open: 2642.95
• 1-Year Change: -34.74%
• Day's Range: 2614.88 - 2644.15

Trade Daiichi Sankyo Company, Limited - 4568

About Daiichi Sankyo Co Ltd

Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.

Financial summary

BRIEF: For the nine months ended 31 December 2021, Daiichi Sankyo Co Ltd revenues increased 10% to Y810.97B. Net income increased 24% to Y94.32B. Revenues reflect Northern America segment increase of 26% to Y179.2B, Europe segment increase of 24% to Y103.97B. Dividend per share remained flat at Y13.50. Basic Earnings per Share excluding Extraordinary Items increased from Y38.99 to Y49.21.

Equity composition

FY'08 1Q&3Q O/S=WAS. 12/07, Name changed from DAIICHI SANKYO CO., LTD. FY'10 Q1 DWAS was estimated. FY'10 Q3 DWAS was estimated. FY'11 Q3 DWAS was estimated.